Biogen Inc (BIIB)

[RedShoulder]

FDA gives Biogen's Aducanumab thumbs down 8-1 vote.

"The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 8-1 (2 uncertain) that the Phase 3 EMERGE study (the one that was successful at the higher dose) evaluating Biogen's (NASDAQ:BIIB) aducanumab in patients with mild Alzheimer's disease was not enough to demonstrate efficacy.

Shares will be poised for a significant drop when trading resumes."

Good news for Anavex AVXL which Alzheimer drug shows safety and efficacy.

Link;
https://seekingalpha.com/news/3633299-fda-thumbs-down-on-biogen-alzheimers-candidate-aducanumab